Separate names with a comma.
Does anyone see an upside in growth chalking the exodus up to a rocky start like most start ups experience in the first 1-2 years (been there done...
is bonus plan even half attainable? I see the drugs are mostly tier 2 on some larger plans, caremark etc. Not terrible, not ideal either.
In the same boat. Seems like it could be a great opportunity going forward...but also seems like its been a tough year and a half for them.
FYI Already did my homework so i have a good idea of past and recent hisotry.
Can anyone give me an honest/objective run down of whats going on at Aerie?